Danish pharmaceutical company Lundbeck has doubled the sale of its anti-depressant Lexapro on the Chinese market in the last four years.
Just this year Lundbeck has experienced a 20 pct growth Chinese market. The growth has mainly been driven by an increasing sale og alzheimers medicin and anti-depressants, Business.dk reports.
The increase in sales is caused by a rise in the number of Chinese who are diagnosed with depression. The last four years Lundbeck’s market share has doubled and is now around 11 pct, which makes them the leading player on the Chinese market of anti-depressants that has six doubled since 2005.
According to Ole Chrintz the manager of Lundbeck’s European and international markets, the growing market is not the only reason for their success.
“The reason why we have succeeded, is that we made a strategic decision to go all in on the Chinese market in 2010,” Ole Chrintz told business.dk